ORPHA:438159
STAT3-related early-onset multisystem autoimmune disease
Query health: suspect — Only one of 2 strategies returned hits (recall-expansion).
Publications
0
Trials
17
Interventional, condition-specific
Researchers
0
Distinct authors in sample
Gene link
ADIPOQ, STAT3
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, genetic, lymphoproliferative syndrome characterized by early onset recurrent infections, lymphadenopathy with and variable autoimmune disorders, including hemolytic anemia, thrombocytopenia, neutropenia, enteropathy, type I diabetes, scleroderma, arthritis, atopic dermatitis, and inflammatory lung disease. Patients commonly have . Variable immunologic findings include decreased regulatory T-cells, hypogammaglobulinemia, and reduction in memory B cells.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0014414
- OMIM:615952
- UMLS:C4014795
- NCIT:C157123
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — ADIPOQ, STAT3
- LiteratureNot found
No matched Europe PMC hits under our query rules Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
17 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (ADIPOQ, STAT3).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
0
We found no papers under this exact name — work may still exist under another label.
0 in the last 10 years · low confidence
Phrase hits: 0 · MeSH hits: 0
Who's working on it?
0
Distinct author names in 0 sampled papers.
Who's working on it?
No author names could be extracted from the sampled publications. Try the Europe PMC query in “How we counted this,” or contact an umbrella rare-disease organisation for researcher referrals.
Clinical research
Is a treatment being tested?
17
interventional trials for this specific condition
17 interventional trials matched this specific condition name; 3 currently recruiting in our sample. 77 trials are registered for autoimmune disease, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
17 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 93.9th percentile).
low confidence · 93.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
17 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07670156·NOT YET RECRUITING·Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
Conditions: JAK1 GOF · STAT1 GOF · STAT3 GOF · STAT5B GOF·Matched via recall expansion
- NCT07262983·RECRUITING·Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Conditions: Hyper IgE Syndrome From STAT3 Mutation · Job s Syndrome · HIES · Lupus·Matched via recall expansion
- NCT06964815·RECRUITING·Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients
Conditions: Glioblastoma · IDH Wild-type and STAT3-positive Glioblastoma·Matched via recall expansion
Broader category: autoimmune disease
77
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06792799·RECRUITING·Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
Conditions: Autoimmune Diseases · Systemic Lupus Erthematosus · Multi-Drug Resistant Nephrotic Syndrome · IgAN - IgA Nephropathy·Matched via name phrase
- NCT07549698·RECRUITING·Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Conditions: Warm Autoimmune Hemolytic Anemia (WAIHA) · ITP - Immune Thrombocytopenia · Warm Autoimmune Hemolytic Anemia · Immune Thrombocytopenic Purpura·Matched via name phrase
- NCT06379646·RECRUITING·An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Conditions: Systemic Lupus Erythematosus · Systemic Sclerosis · Inflammatory Myopathy · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis·Matched via name phrase
- NCT06983964·RECRUITING·Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
Conditions: Autoimmune Disease·Matched via name phrase
- NCT06308978·RECRUITING·A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Conditions: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) · Idiopathic Inflammatory Myositis (IIM) · Systemic Sclerosis (SSc) · Systemic Lupus Erythematosus (SLE)·Matched via name phrase
- NCT06964269·RECRUITING·Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
Conditions: Autoimmune Diseases · Dry Eye · Neurotrophic Keratitis·Matched via name phrase
- NCT07523282·NOT YET RECRUITING·Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
Conditions: Autoimmune Disease · Systemic Lupus Erythematosus · Systemic Sclerosis (SSc)·Matched via name phrase
- NCT06056921·RECRUITING·Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Conditions: SLE (Systemic Lupus) · Sjogren's Syndrome · Systemic Scleroderma · Dermatomyositis·Matched via name phrase
- NCT07586267·RECRUITING·CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
Conditions: Autoimmune Diseases · Systemic Lupus Erthematosus (SLE) · Multi-Drug Resistant Nephrotic Syndrome · IgA Nephropathy (IgAN)·Matched via name phrase
- NCT07507201·RECRUITING·Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
Conditions: Autoimmune Diseases · Systemic Lupus Erthematosus (SLE) · Multi-Drug Resistant Nephrotic Syndrome · IgA Nephropathy (IgAN)·Matched via name phrase
- NCT06633042·NOT YET RECRUITING·The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
Conditions: Autoimmune Disease·Matched via name phrase
- NCT07305116·RECRUITING·CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Conditions: Autoimmune Diseases · Systemic Lupus Erthematosus (SLE) · Multi-Drug Resistant Nephrotic Syndrome · IgA Nephropathy (IgAN)·Matched via name phrase
- NCT00977977·RECRUITING·Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Conditions: Nephrotic Syndrome · Proteinuria · Autoimmune Disease · Glomerular Disease·Matched via name phrase
- NCT06817889·RECRUITING·Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Conditions: Hematopoietic and Lymphatic System Neoplasm · Autoimmune Disease · Respiratory Syncytial Virus Infection·Matched via name phrase
- NCT06557265·RECRUITING·A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Conditions: Lupus Nephritis · Primary Membranous Nephropathy·Matched via name phrase
Observational and natural-history studies
6 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT00006150·RECRUITING·Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
Conditions: Infections · Pneumonia · Immune System Diseases · STAT3 Transcription Factor·Matched via recall expansion
- NCT00001467·RECRUITING·Genetic Analysis of Immune Disorders
Conditions: DOK 8 · STAT1 · GATA2 · Immunodeficiency·Matched via recall expansion
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"STAT3-related early-onset multisystem autoimmune disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"STAT3-related early-onset multisystem autoimmune disease" OR "ADIPOQ" OR "STAT3"
Recall-expansion terms: ADIPOQ, STAT3
Interventional trials matched via: recall-expansion (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 17 interventional · 6 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"autoimmune disease"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: recall-expansion
Parent literature probe: hereditary disease (MONDO:0003847) — 11220 hits
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Zero publications but GenCC Definitive — literature likely indexed under another name; excluded from neglect count
- Trial count (17) far exceeds publication count (0) — trial matching may still be loose
Ingested 2026-07-27T16:13:59.944Z · excluded from neglect metrics
